JP4879745B2 - 置換イソキノリノン - Google Patents

置換イソキノリノン Download PDF

Info

Publication number
JP4879745B2
JP4879745B2 JP2006534084A JP2006534084A JP4879745B2 JP 4879745 B2 JP4879745 B2 JP 4879745B2 JP 2006534084 A JP2006534084 A JP 2006534084A JP 2006534084 A JP2006534084 A JP 2006534084A JP 4879745 B2 JP4879745 B2 JP 4879745B2
Authority
JP
Japan
Prior art keywords
alkyl
fluoro
cycloalkyl
amino
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006534084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507519A (ja
JP2007507519A5 (enExample
Inventor
ロバート エム. スカーボロー,
キム エー. ケイン−マクガイア,
チャールズ ケー. マーロウ,
マーク エス. スミス,
シャオミン ツァン,
Original Assignee
ポートラ ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポートラ ファーマシューティカルズ, インコーポレイテッド filed Critical ポートラ ファーマシューティカルズ, インコーポレイテッド
Publication of JP2007507519A publication Critical patent/JP2007507519A/ja
Publication of JP2007507519A5 publication Critical patent/JP2007507519A5/ja
Application granted granted Critical
Publication of JP4879745B2 publication Critical patent/JP4879745B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006534084A 2003-10-03 2004-09-29 置換イソキノリノン Expired - Fee Related JP4879745B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50840203P 2003-10-03 2003-10-03
US60/508,402 2003-10-03
PCT/US2004/032104 WO2005035520A1 (en) 2003-10-03 2004-09-29 Substituted isoquinolinones

Publications (3)

Publication Number Publication Date
JP2007507519A JP2007507519A (ja) 2007-03-29
JP2007507519A5 JP2007507519A5 (enExample) 2007-11-08
JP4879745B2 true JP4879745B2 (ja) 2012-02-22

Family

ID=34434908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534084A Expired - Fee Related JP4879745B2 (ja) 2003-10-03 2004-09-29 置換イソキノリノン

Country Status (10)

Country Link
US (1) US7294635B2 (enExample)
EP (1) EP1667989A4 (enExample)
JP (1) JP4879745B2 (enExample)
KR (1) KR20060113699A (enExample)
CN (1) CN1863789B (enExample)
AU (1) AU2004279809B2 (enExample)
CA (1) CA2539882A1 (enExample)
IL (1) IL174445A (enExample)
MX (1) MXPA06003625A (enExample)
WO (1) WO2005035520A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006039212A2 (en) * 2004-09-29 2006-04-13 Portola Pharmaceuticals, Inc. Substituted 2h-1,3-benzoxazin-4(3h)-ones
US20080312208A1 (en) * 2005-07-13 2008-12-18 Astrazeneca Ab Pyridine Analogues
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
CN101511815A (zh) * 2006-07-04 2009-08-19 阿斯利康(瑞典)有限公司 新型吡啶类似物
WO2008004941A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
KR101638035B1 (ko) 2007-01-22 2016-07-11 지티엑스, 인코포레이티드 핵 수용체에 결합하는 물질
WO2008133155A1 (ja) 2007-04-19 2008-11-06 Astellas Pharma Inc. 二環式ヘテロ環化合物
KR101509829B1 (ko) * 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 adp 수용체 억제제로 작용하는 화합물을 이용한 병용요법
US20090018166A1 (en) * 2007-07-13 2009-01-15 Astrazeneca Ab New Pyridine Analogues X 161
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
ES2718175T3 (es) * 2014-12-02 2019-06-28 Lilly Co Eli Compuestos de 1-oxo-1,2-dihidroisoquinolin-7-il-(tiofen-2-il-5-sustituido)-sulfonamida, formulaciones que contienen esos compuestos, y su uso como inhibidores de AICARFT en el tratamiento de cánceres
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
CN110914256A (zh) 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011872A1 (en) * 2001-08-02 2003-02-13 Millennium Pharmaceuticals, Inc. Platelet adp receptor inhibitors
JP2003522177A (ja) * 2000-02-04 2003-07-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 血小板adpレセプターインヒビター

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
CA2318199A1 (en) 1998-01-15 1999-07-22 Cor Therapeutics, Inc. Platelet adp receptor inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522177A (ja) * 2000-02-04 2003-07-22 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 血小板adpレセプターインヒビター
WO2003011872A1 (en) * 2001-08-02 2003-02-13 Millennium Pharmaceuticals, Inc. Platelet adp receptor inhibitors

Also Published As

Publication number Publication date
US20050113399A1 (en) 2005-05-26
AU2004279809B2 (en) 2010-07-15
EP1667989A1 (en) 2006-06-14
IL174445A0 (en) 2006-08-01
CA2539882A1 (en) 2005-04-21
CN1863789B (zh) 2010-06-09
MXPA06003625A (es) 2006-08-11
KR20060113699A (ko) 2006-11-02
JP2007507519A (ja) 2007-03-29
IL174445A (en) 2012-02-29
AU2004279809A1 (en) 2005-04-21
US7294635B2 (en) 2007-11-13
WO2005035520A1 (en) 2005-04-21
CN1863789A (zh) 2006-11-15
EP1667989A4 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
JP2007507519A (ja) 置換イソキノリノン
AU2004278030B2 (en) 2,4-Dioxo-3-quinazolinylaryl sulfonylureas
US7205296B2 (en) Substituted 2H-1,3-benzoxazin-4(3H)-ones
US8680139B2 (en) Anti-neoplastic compounds, compositions and methods
JP6281984B2 (ja) 1,2,4−トリアジン−6−カルボキサミドキナーゼ阻害剤
CN104024241A (zh) 尿嘧啶衍生物和其用于医学目的的用途
JPWO2006057270A1 (ja) 含窒素3環化合物
JP2009542641A (ja) 新規ピリジン類縁体
JP5266232B2 (ja) 血小板adp受容体阻害剤としての窒素含有置換ヘテロ環
JP2015523996A (ja) 置換ピコリンアミドキナーゼ阻害剤
HK1093973B (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
HK1111414B (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111114

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111130

R150 Certificate of patent or registration of utility model

Ref document number: 4879745

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141209

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees